Objective To investigate the association between the single nucleotide polymorphisms of interleukin-27 (IL-27) gene and susceptibility to systematic lupus erythematosus (SLE) in Guangxi Zhuang population. Methods In total, 135 patients with SLE and 150 age- and sex-matched human controls of Zhuang nationality were recruited in this study. PCR-restriction fragment length polymorphism (RFLP) analysis and DNA sequencing were performed to analyze the IL-27 gene -964 A/G and -2905 T/G polymorphisms.Results Significant differences were observed in the distribution of IL-27 gene -964 A/G polymorphism (x2 =9.88, P ＜ 0.01 ). The relative risk for SLE in carriers of G allele at position 964 of IL-27 gene was 1.725 times that in carriers of A allele at this position (OR = 1.725,95% CI: 1.227 - 2.425). A significant increase was observed in the frequency of 964G/2905G alleles of IL-27 gene in patients with SLE compared with the controls (10.7% vs. 5.3%, P ＜ 0.01 ), and the 964G/2905G alleles were associated with a significantly increased risk for SLE (OR = 2.351, 95% CI: 1.228 - 4.501 ). Conclusions The IL-27 gene -964 A/G polymorphism is associated with the development of SLE, and the -964 G allele may increase the genetic susceptibility to SLE.

Objective To study the changes of serum protein spectrum in patients with systematic lupus erythematosus (SLE) in order to screen specific protein markers. Methods Serum samples from 72 patients with SLE and 85 age- and sex-matched controls were assessed using surface-enhanced laser desorp-tion/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) with weak cation exchange (CM10) pro-rein chip. Forty samples from the patients and 50 control samples were randomly selected to serve as a pre-liminary training set; significantly different protein peaks were automatically chosen for the system training and development of a decision classification tree model. The validity of the model was then challenged with a blind test set (including another 32 samples from patients and 35 from human controls). Results A total of 73 effective protein peaks were detected within the mass/charge ratio (m/z) interval 2000 - 50000, among which, 15 protein peaks significantly differed between patients with SLE and controls (P < 0.01). Three pro-tein peaks with an m/z value of 4001, 6305 and 7356 were automatically chosen as a biomarker pattern in the training set that discriminated patients with SLE from controls with a sensitivity of 90.0% (36/40), speci-ficity of 92.0% (46/50) and accuracy rate of 91.1% (82/90). When the SELDI marker pattern was tested with the blinded test set, it yielded a sensitivity of 87.5% (28/32), specificity of 91.4% (32/35) and accuracy rate of 89.6% (60/67). Conclusions SELDI-TOF-MS protein chip could be used to screen serum protein for SLE, and the decision classification tree model with these biomarkers may favor the diagnosis of SLE.

Objective This study aimed to investigate the expression of Cyclin E protein in the progress of occurrence and development of gastric cancer and lymphonode metastatic cancer.Methods The expression of Cyclin E protein analyzed by immunohistochemistry in gastric tissue array included of normal gastric mucosa,cancer side tissues,atypical hyperplasia tissues,primary cancer tissues and lymphonode metastatic cancer tissues.Results The positive expression rate of Cyclin E protein was 14.3％,20.0％,34.7％,85.1％ and 82.9％ in normal gastric mucosa,atypical hyperplasia tissue,carcinoma side tissue,primary cancer and lymphonode metastatic cancer,respectively.Compared with normal gastric mucosa and carcinoma side tissues and atypical hyperplasia tissues,the Cyclin E protein in primary cancer and lymphonode metastatic carcinoma tissues was over-expression ( P ＜ 0.01 ).Conclusions The Cyclin E protein was a possible molecular marker that can be used to diagnosis gastric cancer and lymphaden metastasis cancer.

STGC3, a novel tumor related gene, was cloned recently. The previous studies indicated that STGC3 can inhibit the proliferation of CNE2 cell line in vitro. To examine the effect of STGC3 on the tumorigenicity of CNE2 cell line and explore its mechanism in nude mice. The Tet/pTRE/CNE2-STGC3 cell line was planted under the front leg skin of nude mice and induced by doxycycline (Dox). The mRNA and protein level of STGC3 in transplanted tumor tissues were detected with RT-PCR and Western Blotting. The apoptosis ratio of the tumor cell was analyzed with flow cytometry. STGC3, Bcl-2 and Bax proteins were examined by immunohistochemistry method. The results indicated that high level of STGC3 expression can inhibit tumorigenicity of CNE2 cell line in nude mice. Tumor grew slowly, later and smaller. Cell apoptotic percentage increased. Bcl-2 protein expression was down-regulated and Bax protein expression was up-regulated in Tet/pTRE/CNE2-STGC3 cell line (P

BACKGROUND:Thoracic spinal cord injury often leads to double lower limb paralysis. Paraplegia walking orthosis can improve lower limb dysfunction, improve the daily living activity, and regain the ability to stand and walk in patients with paraplegia. OBJECTIVE:To discuss the effects of paraplegia walking orthosis on muscle spasticity and recovery of function of the affected lower extremity in patients with thoracic spinal cord injury. METHODS:The 20 patients with thoracic spinal cord injury (T5-12), according to the damage plane by American Spinal Injury Association standard, were divided into complete damage group and incomplete damage group (n=10). Al patients were fitted out paraplegia walking orthosis. They received residual muscle strength training, sitting balance training, and transfer training prior to assembly, and then subjected to standing exercise within paralel bar, balance and transfer training, and walking aid devices training indoor and outdoor, and elbow crutch training on foot after the assembly. RESULTS AND CONCLUSION:Compared with pre-treatment, American Spinal Injury Association score increased at 12 weeks after treatment with paraplegia walking orthosis, and sensation did not obviously alter. Spasm worsened with prolonged course of disease in the complete damage group. At 12 weeks after treatment, American Spinal Injury Association score increased, sensation apparently improved, and the spasm did not change with time in the incomplete damage group. Activities of daily living (modified Barthel index, and functional independence evaluation) evidently improved in both groups. Compared with 2 weeks, the 10-m walking time was noticeably reduced and the 6-minute walking distance was prolonged at 12 weeks in both groups. These results confirm that paraplegia walking orthosis fitted out in patients with thoracic spinal cord injury significantly improves the patient’s motor function, activities of daily living and walking ability, and also has certain influence on muscle spasm control.